The above commentary is similar to what has been the case with pneumococcal pneumonia, where the spectrum includes severities from mild (eg, “walking pneumonia”) to overwhelming. And while there may be an anticipated cadre “typical” for disease, it is well appreciated that it occurs in patients of all ages, and in those without obvious comorbidities. Also similar to pneumococcal pneumonia is the appreciation that we can often treat with shorter antibiotic courses than was generally appreciated and what has been historically recommended. The current investigation, on account of protocols not specifically aimed at therapy for legionellosis, utilized durations of treatment as little as 5 days with generally excellent outcomes, although numbers are small. Indeed, almost 20% of patients were treated with this short duration, similar to recommendations for management of uncomplicated pneumococcal pneumonia in patients with good initial response.8 Recently, other data have demonstrated the effectiveness of azithromycin in 25 patients hospitalized with CAP caused by L pneumophila.,10 Mean duration of IV plus oral therapy was < 8 days, with good outcomes. Although the pharmacokinetics and pharmacodynamics of azithromycin are dissimilar to those of the fluoroquinolones, this report adds further substance to the concept of shortened therapy for this disease.